QN
Quoin Pharmaceuticals, Ltd.
QNRX · NASDAQ
$6.90 -0.29% (-$0.02)
1M +30.26%
Market Cap $14.2M
P/E Ratio -
Div. Yield -
ROE 304.87%
Bulios Fair Price
$10.09
46.2% upside
Current Price
$6.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, QNRX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
57 /100
Fair P/B 3.60x
P/E N/A
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 20.99%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 359.18%
Asset turnover 0.00x
ROE 304.87%
Debt
96 /100
Low Debt/Equity 0.00x
Current ratio 1.76x
Int. coverage N/A
Stability
8 /100
Unstable Beta 1.66x
Profitable years 0
EPS volatility 837.92%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about QNRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Myers
Employees
4
Headquarters
Ashburn
Upcoming events
05 NOV
Earnings
Upcoming earnings report